A Phase I Open-label, Randomized, Safety and Efficacy Study of SANGUINATE at Two Doses Levels Versus Hydroxyurea in Sickle Cell Disease (SCD) Patients.

Trial Profile

A Phase I Open-label, Randomized, Safety and Efficacy Study of SANGUINATE at Two Doses Levels Versus Hydroxyurea in Sickle Cell Disease (SCD) Patients.

Completed
Phase of Trial: Phase I

Latest Information Update: 05 Dec 2014

At a glance

  • Drugs PEG-haemoglobin carbon monoxide (Primary) ; Hydroxycarbamide
  • Indications Sickle cell anaemia
  • Focus Therapeutic Use
  • Sponsors Prolong Pharmaceuticals
  • Most Recent Events

    • 02 Dec 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 10 May 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top